Non-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a Treatment for Subjects With Different HRD Tumor Status and With Platinum-Sensitive, Relapsed, High-Grade Serous or High-Grade Endometrioid Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That Have Received at Least 1 Prior Line of Chemotherapy
Phase of Trial: Phase II
Latest Information Update: 07 Jan 2018
At a glance
- Drugs Olaparib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 16 Aug 2017 Planned End Date changed from 17 Jan 2019 to 23 Oct 2019.
- 16 Aug 2017 Planned primary completion date changed from 17 Jan 2019 to 23 Oct 2019.
- 11 Jul 2017 Planned End Date changed from 18 Dec 2019 to 17 Jan 2019.